Thanks to the five of you who responded to the recent question about F&A
charged on federally funded clinical trials.  The information I'm
seeking is should there be a concern about charging the full negotiated
F&A rate to a federal clinical trial while charging 20 to 30% to a
pharmaceutical firm sponsored clinical trial.  How is the disparate
treatment defensible or is the answer so obvious so as not to require an
explanation.  If you are willing to respond directly to my email address
I would certainly appreciate your wisdom.  thanks.  see ya.

--
Kent Walker
Chief Contract Administrator
University of North Carolina-CH
Office of Contracts & Grants
440 West Franklin Street
Chapel Hill, NC 27599
Voice:  919-962-1353
E-Mail:  xxxxxx@UNC.EDU